<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864656</url>
  </required_header>
  <id_info>
    <org_study_id>phenylephrine test</org_study_id>
    <nct_id>NCT00864656</nct_id>
  </id_info>
  <brief_title>Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine</brief_title>
  <official_title>Comparative Study of Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 1, 2 or 4 Drops of 10% Phenylephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to quantify eyelid position changes in tested and opposite
      eyes in ptosis patients submitted to 1, 2 or 4 drops of 10% phenylephrine in one eye. The
      secondary objective is to correlate the eye dominance, severity and laterality of ptosis with
      eyelid position changes in these 3 groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study conducted in involutional ptosis patients, which
      will be submitted to instillation of a single drop of 10% phenylephrine in one eye(Group 1),
      2 drops (G2) or 4 drops ( G3).

      Video camera will record the images of both eyes before and after drug application at 3, 10,
      15 and 30 minutes. The images will be edited to analyze upper and lower lid height.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Upper lid height before and after phenylephrine test lower lid height before and after phenylephrine test</measure>
    <time_frame>3, 10, 15 and 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scobee test to detect eye dominance</measure>
    <time_frame>15 minutes before 10% phenylephrine instillation</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Blepharoptosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients submitted to application of 1 drop of 10% phenylephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients submitted to application of 2 drops of 10% phenylephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients submitted to application of 4 drops of 10% phenylephrine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Involutional blepharoptosis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Involutional blepharoptosis

          -  Upper Margin-reflex distance less or equal 2.0mm

          -  Good fixation and collaboration

        Exclusion Criteria:

          -  Previous eyelid surgeries

          -  Use of adrenergic or sympathicomimetics drugs

          -  Myopathies

          -  Thyroid orbitopathy

          -  Non-controlled cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzana Matayoshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Opthalmology Dept.Sao Paulo University General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmology Dept. University of Sao Paulo General Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Nunes TP, Matayoshi S. [Phenylephrine 10% eye drop action in the eyelid position in healthy subjects]. Arq Bras Oftalmol. 2008 Sep-Oct;71(5):639-43. Portuguese.</citation>
    <PMID>19039456</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>March 18, 2009</last_update_submitted>
  <last_update_submitted_qc>March 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Suzana Matayoshi</name_title>
    <organization>Clinica Oftalmologica HCFMUSP</organization>
  </responsible_party>
  <keyword>adrenergic alpha-agonists</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>drug effects</keyword>
  <keyword>diagnostic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharoptosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

